{
  "cardiorenal_high_risk": [
    "In adults with T2DM and HF or CKD, SGLT2 inhibitors are recommended to reduce HF hospitalization, slow eGFR decline, and reduce CV events, independent of A1c.",
    "GLP-1 receptor agonists reduce MACE and weight, but SGLT2 inhibitors have stronger evidence for HF and CKD outcomes."
  ],
  "ascvd": [
    "In adults with T2DM and established ASCVD or multiple risk factors, GLP-1 receptor agonists or SGLT2 inhibitors with proven benefit are recommended to reduce MACE and CV mortality.",
    "GLP-1 receptor agonists especially reduce stroke; SGLT2 inhibitors reduce HF hospitalizations and CKD progression."
  ],
  "obesity_high_risk": [
    "For T2DM with obesity and high CV risk, GLP-1 receptor agonists (and dual GIP/GLP-1 RA) provide strong A1c lowering, substantial weight loss, and CV risk reduction.",
    "Weight loss of 5â€“15% improves glycemia and reduces cardiovascular and liver risk."
  ],
  "standard_new_t2dm": [
    "For most people with newly diagnosed T2DM without cardiorenal disease, metformin is recommended as initial pharmacologic therapy due to efficacy, safety, and low cost.",
    "If A1c is more than about 1.5% above target, initial combination therapy can be considered."
  ]
}